Representatives from the drugmaker Mylan want to meet with Sen. Chuck Grassley, R-Iowa, to discuss a probe into whether the company bilked Medicaid out of $1.27 billion, according to a published report.
Mylan, which produces the allergy drug EpiPen, wants to meet with Grassley on June 7 to discuss a subpoena threat over documents pertaining to Medicaid's rebate program, according to a report in the Street.
Grassley pointed to a Department of Health and Human Services investigator general's report last week that showed Medicaid overpaid by $1.27 billion for the EpiPen from 2006 to 2016. The reason for the payment was due to Mylan's misclassification of the EpiPen as a generic drug.
Drugmakers must provide rebates for their products to be offered on Medicaid. A brand-name drug must give a rebate of 23 percent of the average price and a generic one must give 13 percent.
Mylan classified the EpiPen as a generic for years when it is actually a brand name drug.
The company is negotiating a final settlement with the federal government over the allegations that it misclassified the drug.
Mylan told the Washington Examiner that it has met and "continue to meet with many congressional offices, including Sen. Grassley's."